Figure 3.
FLT3-TKD subclone architecture based on ultradeep sequencing results, inserted into the time line of the disease course. A heterozygous FLT3-TKD mutation was present in virtually all cerebrospinal fluid (CSF) cells at meningeal relapse. Interestingly, the mutation could be traced back to a tiny FLT3-TKD clone present in the bone marrow sample from first diagnosis. BM, bone marrow; AIDA, ATRA plus idarubicin; ATRA, all-trans retinoic acid; ATO, arsenic trioxide.